研究方向
主要从事造血干细胞移植和恶性血液病的应用基础和临床研究,总体思路是：以解决血液病临床重大问题为导向，结合实验室机制研究及生物学标记技术，形成具有可操作性的诊疗体系。目前采用“临床病例模型—体外实验及动物模型—完善临床体系”的研究模式，系统性地研究（1）单倍型造血干细胞移植及免疫机制；（2）基于分子标记的血液病分层、个性化诊疗体系；（3）造血干细胞、白血病干细胞与微环境相互作用机制。
代表性科研论文
1. Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014;370(19):1864-1866.
2. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871-879.
3. Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ. Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol. 2016;34(16):1855-1863.
4. Kong Y, Cao XN, Zhang XH, Shi MM, Lai YY, Wang Y, Xu LP, Chang YJ, Huang XJ. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood. 2018;131(11):1219-1233.
5. Shi MM, Kong Y, Song Y, Sun YQ, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128(25):2988-2999.
6. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843-850.
7. Kong Y, Wang Y, Zhang YY, Shi MM, Mo XD, Sun YQ, Chang YJ, Xu LP, Zhang XH, Liu KY, Huang XJ. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3(8):1303-1317.
8. Wang K, Lv M, Chang YJ, Zhao XY, Zhao XS, Zhang YY, Sun YQ, Wang ZD, Suo P, Zhou Y, Liu D, Zhai SZ, Hong Y, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ. Early myeloid-derived suppressor cells (HLA-DR(-)/(low)CD33(+)CD16(-)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol. 2019;12(1):31.
